Global Artificial Blood Market was valued at USD 3,760 million in 2023 and is projected to reach USD 7,194.83 million by 2031, growing at a CAGR of 8.7% during the forecast period 2024-2031.
Artificial blood serves as a critical alternative to traditional blood transfusions by mimicking oxygen transport functions, especially in scenarios where donor blood is unavailable. Advances in synthetic production, recombinant biochemical technology, and chemical isolation are driving the market, making artificial blood a viable substitute for emergency trauma cases, organ transplants, and chronic blood disorders.
This report provides an in-depth analysis of market dynamics, segmentation, regional insights, key players, and emerging opportunities, offering stakeholders comprehensive insights into the evolving artificial blood market.
Download Free Sample: https://www.datamintelligence.com/download-sample/artificial-blood-market
Market Size and Growth
- 2023 Market Value: USD 3,760 million
- 2031 Projected Market Value: USD 7,194.83 million
- CAGR (2024-2031): 8.7%
Key Market Trends
- Technological Innovations in Artificial Blood Production
- Hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbon (PFC) emulsions are improving oxygen transport efficiency.
- New approaches like stem cell-derived blood and recombinant biochemical techniques are expanding possibilities.
- Increasing Demand for Blood Substitutes in Trauma Care
- Artificial blood offers immediate solutions in trauma cases, battlefield injuries, and disaster scenarios where donor blood is scarce.
- Example: Nara Medical University (July 2024) announced a clinical study for transfusion-ready artificial red blood cells in emergency care settings.
- Rising Prevalence of Chronic Blood Disorders
- Anemia, cardiovascular diseases, and maternal conditions are driving demand for alternative blood products.
- Example: The World Health Organization (WHO, 2023) estimates that 17 million people die annually from non-communicable diseases (NCDs), many of which involve blood-related conditions.
- Regulatory Advancements and Research Funding
- Governments and private organizations are investing in artificial blood R&D to improve safety and effectiveness.
- Example: Bioxytran, Inc. (July 2024) partnered with the Heme Foundation to develop a universal oxygen carrier (UOC) as an alternative to blood transfusions.
Customize Your Scope: https://www.datamintelligence.com/customize/artificial-blood-market
Market Dynamics
1. Rising Advancements in Research and Development
- Ongoing R&D efforts are focused on improving safety, reducing immunological reactions, and enhancing oxygen-carrying capacity.
- Example: NIHR-funded RESTORE clinical trial (2022) launched to evaluate lab-grown red blood cells in human subjects.
2. Growing Need for Artificial Blood in Emergency & Military Applications
- Battlefield and disaster scenarios require immediate and durable blood substitutes, making artificial blood a vital solution.
- Example: DARPA (2024) allocated $46.4 million for a research project aimed at developing a room-temperature storable whole blood alternative for military use.
3. Adverse Effects Limiting Widespread Adoption
- Hemoglobin-based oxygen carriers (HBOCs) may cause hypertension, jaundice, stroke, and other side effects, raising concerns about safety.
- These adverse effects reduce artificial blood adoption in surgical and routine transfusion settings.
Market Segmentation
By Product Type:
- Hemoglobin-Based Oxygen Carriers (HBOCs) (Largest Segment)
- Perfluorocarbon Emulsions (PFCs)
By Source:
- Human Hemoglobin
- Animal Hemoglobin
- Stem Cells
- Synthetic Polymers
- Microorganisms
- Others
By Process:
- Synthetic Production
- Chemical Isolation
- Recombinant Biochemical Technology
By Application:
- Anemia
- Organ Transplantation
- Injuries & Trauma
- Cardiovascular Diseases
- Maternal Conditions
- Others
By End-User:
- Hospitals
- Clinics
- Blood Banks
- Research Institutes
- Others
By Region:
- North America (Largest Market Share)
- Europe
- Asia-Pacific (Fastest Growing Region)
- South America
- Middle East & Africa
Regional Insights
1. North America – Market Leader
- Advanced research funding and trauma care advancements drive market growth.
- Example: The University of Maryland School of Medicine (UMSOM) is managing a $46.4 million DARPA-funded artificial blood research project.
- Rising cases of blood disorders and battlefield injuries further increase demand.
2. Asia-Pacific – Fastest Growing Region
- High population density and increasing medical research investments accelerate market growth.
- Example: Nara Medical University (Japan) announced a 2025 clinical trial for artificial red blood cell transfusions.
- India and China are investing heavily in biopharmaceutical research, driving innovation in synthetic blood technologies.
3. Europe – Rising Adoption of Artificial Blood Products
- Strong regulatory framework and research grants support market expansion.
- Example: Bioxytran, Inc. launched a joint venture (July 2024) with the Heme Foundation for universal oxygen carrier (UOC) development.
Key Market Players:
- Hemarina
- KaloCyte, Inc.
- SpheriTech Limited
- Hemoglobin Oxygen Therapeutics LLC
Recent Innovations & Investments:
- July 2024: Bioxytran Inc. announced a Joint Venture with the Heme Foundation to develop a Universal Oxygen Carrier (UOC) as an alternative to blood transfusions.
- July 2024: Nara Medical University launched a clinical study on artificial red blood cells for emergency transfusions in Japan.
- November 2022: NIHR initiated the RESTORE clinical trial, testing lab-grown red blood cells in human patients.
Why Purchase This Report?
✔ Comprehensive Market Insights: Breakdown by product type, source, process, application, and region.
✔ Competitive Analysis: Insights into leading players, emerging competitors, and new innovations.
✔ Regulatory & Pricing Trends: Analysis of FDA and EMA regulations impacting artificial blood development.
✔ Industry Data & Forecasts: Market projections, supply chain insights, and investment opportunities.
✔ Healthcare Impact Analysis: Examination of real-world applications and adoption trends.
Target Audience (2024-2031)
- Biotech & Pharmaceutical Companies
- Blood Banks & Transfusion Centers
- Medical Researchers & R&D Labs
- Healthcare Investors & Venture Capitalists
- Regulatory Agencies & Policymakers
- Military & Emergency Medical Service Providers
This report provides detailed insights, featuring 53+ tables, 47+ figures, and 176+ pages of expert market analysis to help stakeholders navigate the evolving artificial blood market.
Contact Us
Company Name: DataM Intelligence
Contact Person: Sai Kumar
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us –
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
